Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TruScreen Group Ltd. ( (AU:TRU) ) has provided an update.
TruScreen Group has announced that long-serving independent non-executive director Christopher Horn will retire following the filing of the company’s preliminary final results, expected around 31 May 2026. Horn, a former senior KPMG partner, has chaired the audit committee and played a key role in TruScreen’s listings on NZX and ASX, as well as in strengthening its financial reporting and governance.
Executive chairman Tony Ho credited Horn with helping guide TruScreen’s evolution from a women’s health start-up to a WHO-recognised leader in AI-based cervical cancer screening. Upon his retirement, the board will install current director Christine Pears as chair of the audit committee and plans to appoint a new Australia-based non-executive director, signalling continuity in governance during the company’s global expansion.
More about TruScreen Group Ltd.
TruScreen Group Ltd is a medical device company focused on women’s health, specialising in AI-enabled cervical cancer screening technology. Its TruScreen Ultra device provides real-time detection of cervical tissue abnormalities without traditional lab-based sampling and is approved or registered in multiple markets, including Australia, China, the UK, Russia, Mexico, Vietnam, and others.
For detailed information about TRU stock, go to TipRanks’ Stock Analysis page.